January 7, 2016

United States, New York

Mercer announced today it has formed a strategic alliance with Progyny to provide employers and their employees with the innovative SMART™ (Science and Member-Driven Assisted Reproductive Technology) fertility benefit product which will enable companies to significantly reduce newborn intensive care unit (NICU) and associated high-risk maternity-related costs, while increasing access and positive outcomes.

The Progyny Suite of SMART Fertility Services includes a comprehensive national network of fertility clinics; clinic quality and cost transparency; and personal concierge services delivered by Patient Care Advocates.  Benefits include: egg freezing, IVF treatment, non-IVF fertility treatments, and medications. In addition, genetic counselors, fertility nurses, psychologists, and surrogacy counselors will be available to patients for an end-to-end fertility solution. Employees and employers will also have access to the Progyny Patient Portal with over 250,000 pages of fertility information and education.

“Fertility benefits are becoming a key topic for employers and employees alike,” said Dr. David Kaplan, leader of Mercer Health Innovation LABS. “This interest is not only being driven by talent and retention-related issues, but also by the high cost for employers who,  whether they offer infertility benefits or not, are still incurring much of the NICU and associated high-risk maternity-related expenses. Progyny is helping both employers and their employees better manage the financial and emotional burden of infertility.”

“We’re proud that Progyny has developed a fertility benefit that includes the latest fertility technology to greatly improve pregnancy success,” said Karin Ajmani, President, Healthcare Services of Progyny. “With one in six women in the US struggling with infertility, we know these demands will continue to grow, and our benefit design coupled with support services takes the guess work out of this emotional and often costly journey. We’re thrilled that our alliance with Mercer won’t just change lives, but help create healthy families.”

The Mercer strategic alliance with Progyny represents one of the inaugural solutions brought to market by Mercer’s Health Innovation LABS team. The Mercer LABS team continuously researches the health care landscape, evaluates emerging trends and identifies promising solutions. The LABS team engages with innovative companies to accelerate the development of their ideas and test them with forward-thinking employers. Their work helps employers navigate the rapidly changing healthcare environment, launch clinically-impactful programs and improve the health of their employees and families.

Figure 1: Infertility Treatment Today

Sources: RMANJ: Infertility In America 2015. Basking Ridge. Retrieved 12 8, 2015, from; Assisted Reproductive Technology Surveillance — United States, 2010, Sunderam, S et al. Retrieved 1 6, 2016, from; 2009 - 2013 SART Data, Retrieved from;    Analysis of Advanced Reproductive Births from 2005-2009 conducted by large health plan; Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates, Forman, E et al, Retrieved 1 6 2016 from; March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global Action Report on Preterm Birth. Eds CP Howson, MV Kinney, JE Lawn. World Health Organization. Geneva, 2012; ASRM; American Society for Reproductive Medicine. (2012). Age and Fertility: A Guide for Patients; 2012. Retrieved from;  How Plans Can Improve Outcomes And Cut Costs for Preterm Infant Care, Kornhauser, M

About Mercer

Mercer is a global consulting leader in talent, health, retirement and investments. Mercer helps clients around the world advance the health, wealth and careers of their most vital asset – their people. Mercer’s more than 20,000 employees are based in 43 countries and the firm operates in over 140 countries.  Mercer is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy and people. With annual revenue of $13 billion and 57,000 colleagues worldwide, Marsh & McLennan Companies is also the parent company of Marsh, a leader in insurance broking and risk management; Guy Carpenter, a leader in providing risk and reinsurance intermediary services; and Oliver Wyman, a leader in management consulting. For more information, visit Follow Mercer on Twitter @Mercer.

About Progyny
Progyny is a best-in-class health care company providing consumers effective fertility outcomes by aligning science, technology, clinics and patients. Offering unique fertility solutions to consumers, employers and health plans, Progyny is the first company with a cost-efficient fertility benefit product to better manage women’s fertility while reducing high maternity and NICU-related costs. Progyny’s portfolio of solutions includes: Progyny Fertility Benefits - the first cost-efficient fertility benefit solution for employers and health plans,, the country’s leading patient-matching technology platform serving the fertility industry;, a national network of over 185 top fertility doctors specializing in egg freezing; and, the only multi-cycle IVF savings program created by patients for patients; and The Eeva™ Test, the first and only FDA-cleared test to aid in embryo selection. Progyny is privately held and its investors include Kleiner Perkins Caufield & Byers, TPG Biotech, SR One and MS Ventures. The company is headquartered in New York, NY, with operations in Menlo Park, CA. For more information, please visit and follow us on Twitter @Progyny.